FULL DETAILS (Read-only)  -> Click Here to Create PDF for Current Dataset of Trial
CTRI Number  CTRI/2025/07/091413 [Registered on: 22/07/2025] Trial Registered Prospectively
Last Modified On: 11/12/2025
Post Graduate Thesis  No 
Type of Trial  PMS 
Type of Study   Medical Device 
Study Design  Single Arm Study 
Public Title of Study   Arthroscopy Implants for Shoulder 
Scientific Title of Study   A Prospective, Multi-centre, Single-arm, Open-label, Post market clinical follow-up study to Evaluate Safety and Performance of the Arthroscopy Implants for Shoulder In a Real-World Setting. 
Trial Acronym  NIL 
Secondary IDs if Any  
Secondary ID  Identifier 
MHCPL/Arthroscopy Implants V 1.0.0 dated 12 Sept 2024  Protocol Number 
 
Details of Principal Investigator or overall Trial Coordinator (multi-center study)  
Name  Dr Kirankumar Shetty 
Designation  DGM - Product Performance & Engineering Department  
Affiliation  Meril Life Sciences Pvt. Ltd 
Address  Buiding number 6, 3rd floor, Near Bilakhia Stadium, Survey no 135,139,Muktanand marg, Chala, Vapi-396191, Gujarat, India Valsad

Valsad
GUJARAT
396191
India 
Phone  9743700109  
Fax    
Email  kirankumar.shetty@merillife.com  
 
Details of Contact Person
Scientific Query
 
Name  Dr Kirankumar Shetty 
Designation  DGM - Product Performance & Engineering Department  
Affiliation  Meril Life Sciences Pvt. Ltd 
Address  Buiding number 6, 3rd floor, Near Bilakhia Stadium, Survey no 135,139,Muktanand marg, Chala, Vapi-396191, Gujarat, India Valsad


GUJARAT
396191
India 
Phone  9743700109  
Fax    
Email  kirankumar.shetty@merillife.com  
 
Details of Contact Person
Public Query
 
Name  Dr Kirankumar Shetty 
Designation  DGM - Product Performance & Engineering Department  
Affiliation  Meril Life Sciences Pvt. Ltd 
Address  Buiding number 6, 3rd floor, Near Bilakhia Stadium, Survey no 135,139,Muktanand marg, Chala, Vapi-396191, Gujarat, India Valsad


GUJARAT
396191
India 
Phone  9743700109  
Fax    
Email  kirankumar.shetty@merillife.com  
 
Source of Monetary or Material Support  
Meril Healthcare Pvt. Ltd. Meril Park, H1-H3, Survey No. 1575 and 1088, Muktanand Marg, Chala, Vapi, Valsad, Gujarat– 396191 
 
Primary Sponsor  
Name  Meril Life Sciences Pvt Ltd 
Address  Near Bilakhia Stadium, Survey no 135/139,Muktanand marg, Chala, Vapi-396191, Gujarat, India  
Type of Sponsor  Other [Medical Device Company ] 
 
Details of Secondary Sponsor  
Name  Address 
NIL  NIL 
 
Countries of Recruitment     India  
Sites of Study
Modification(s)  
No of Sites = 3  
Name of Principal Investigator  Name of Site  Site Address  Phone/Fax/Email 
Dr Vinay Tantuway  Arthros Multispecialty Hospital,  328/2/4/1 Dargah Bypass, Link Road, MR-9, Khajrana, Indore, Madhya Pradesh 452016
Indore
MADHYA PRADESH 
9893430089

vinayforever@gmail.com 
Dr Raghu Nagaraj  Kauvery Hospital  2371/3, Old HAL Airport Varthur Rd, Munnekolala, Marathahalli, Bengaluru, Karnataka 560037
Bangalore
KARNATAKA 
9535326407

rgh_nagaraj@yahoo.com 
Dr Dhammapal Bhamare   Sainath Hospital  Sant Nagar, Moshi Pradhikaran, Pune Nashik Highway, Moshi, Pune, Maharashtra, 412105, India.
Pune
MAHARASHTRA 
7507899338

drbhamareds@gmail.com 
 
Details of Ethics Committee
Modification(s)  
No of Ethics Committees= 3  
Name of Committee  Approval Status 
Central Independent Ethics Committee  Approved 
Kauvery Hospital, Institutional Ethics Committee  Approved 
Rectitude ethics Committee  Approved 
 
Regulatory Clearance Status from DCGI  
Status 
Not Applicable 
 
Health Condition / Problems Studied  
Health Type  Condition 
Patients  (1) ICD-10 Condition: S429||Fracture of shoulder girdle, partunspecified,  
 
Intervention / Comparator Agent  
Type  Name  Details 
Intervention  NIL  NIL 
Comparator Agent  NIL  NIL 
 
Inclusion Criteria  
Age From  18.00 Year(s)
Age To  99.00 Year(s)
Gender  Both 
Details  1.The Subjects who are eligible for the arthroscopy system, which is used in the surgical procedures related to shoulder ligament fracture fixation, are included in the study.
2.Arthroscopy Shoulder System implants are intended to be used in both men and non-pregnant women of age 18 years or above.
3.The Subjects who require connective tissue tendon repairs for elbow, hand/wrist, and shoulder.
4.Subjects who require general soft tissue approximation and/or ligation, including orthopedic procedures, are included in the study.
5.The Subject must be willing and able to provide written Informed Consent by signing and dating the IRB or EC approved Informed Consent form. If the Subject is not able to write on behalf of the Subject, the Subject`s Legally acceptable representative (LAR) can fill out the
informed consent. When a Subject and LAR are
illiterate, a literate impartial witness is required during consenting. 
 
ExclusionCriteria 
Details  1.Systemic or acute or chronic infection at the surgical site.
2.Known allergy or sensitivity to product materials.
3.Insufficient tissue coverage in the surgical area.
4.A subject who is unwilling or unsuitable for
postoperative instructions.
5.Pregnant women are excluded from the study.
6.Any medical or surgical condition that would preclude the potential benefit of the operation.
7.Fever or leukocytosis.
8.Any medical or surgical condition that could affect the potential benefit of the operation.
9.The Subject who is unwilling or unable to sign the Informed Consent Document will be excluded from the study. 
 
Method of Generating Random Sequence   Not Applicable 
Method of Concealment   Not Applicable 
Blinding/Masking   Not Applicable 
Primary Outcome  
Outcome  TimePoints 
1.Implant failure rate
2.Reoperation rate
3.Intra-operative Complications 
1.Time Frame: Intra-operative, 3 weeks ± 10 days, 3 months ± 15 days, 6 months ± 15 days, 1 year ± 30 days, 2 years ± 30 days
2.Time Frame: 3 weeks ± 10 days, 3 months ± 15 days, 6 months ± 15 days, 1 year ± 30
days, 2 years ± 30 days
3.Time Frame: Intraoperative 
 
Secondary Outcome  
Outcome  TimePoints 
1.Implant failure rate
2.Sugaya Score
3.Reoperation rate
4.Constant-Murley score
5.Wound Complications
6.Visual Analog Scale Pain Score
7.Range of Motion
8.Length of Hospital Stay
9.SF-12 Questionnaire
10.Radiographic Analysis
11.Adverse Events related to the device 
1.Time Frame: 3 years ± 30 days, 4 years ± 30 days, 5 years ± 30 days
2.Time Frame: 6 months ± 15 days
3.Time Frame: 3 years ± 30 days, 4 years ± 30 days, 5 years ± 30 days
4.Time Frame: Pre-operative,
3 weeks ± 10 days, 3 months ± 15 days, 6 months ± 15
days, 1 year ± 30 days, 2 years ± 30 days, 3 years ± 30
days, 4 years ± 30 days, 5 years ± 30 days
5.Time Frame: Discharge, 3
weeks ± 10 days, 3 months ± 15 days, 6 months ± 15 days, 1 year ± 30 days, 2 years ± 30 days, 3 years ± 30 days, 4 years ± 30 days, 5 years ± 30 days
6. Time Frame: Preoperative, 3 weeks ± 10 days, 3 months ± 15 days, 6 months ± 15 days, 1 year ± 30 days, 2 years ± 30
days, 3 years ± 30 days, 4 years ± 30 days, 5 years ±
30 days
7.Time Frame: Pre-operative, 3
weeks ± 10 days, 3 months ± 15 days, 6 months ± 15 days, 1 year ± 30 days, 2 years ± 30 days, 3 years ± 30 days, 4 years ± 30 days, 5 years ± 30 days
8.Time Frame: Admission to
discharge
9.Time Frame: Pre-operative, 3 weeks ± 10 days, 3 months ± 15 days, 6 months ± 15 days, 1 year ± 30 days, 2 years ± 30 days, 3 years ± 30 days,4 years ± 30 days, 5 years ± 30 days
10.Time Frame: Preoperative, 6 months ± 15 days
11.Time Frame: Discharge, 3 weeks ± 10 days, 3 months ± 15 days, 6 months ± 15 days, 1 year±30 days, 2 years ± 30 days, 3 years ± 30 days, 4 years ± 30 days, 5 years ± 30 days 
 
Target Sample Size   Total Sample Size="110"
Sample Size from India="110" 
Final Enrollment numbers achieved (Total)= "Applicable only for Completed/Terminated trials"
Final Enrollment numbers achieved (India)="Applicable only for Completed/Terminated trials" 
Phase of Trial   Post Marketing Surveillance 
Date of First Enrollment (India)   21/08/2025 
Date of Study Completion (India) Applicable only for Completed/Terminated trials 
Date of First Enrollment (Global)  Date Missing 
Date of Study Completion (Global) Applicable only for Completed/Terminated trials 
Estimated Duration of Trial   Years="5"
Months="0"
Days="0" 
Recruitment Status of Trial (Global)   Not Applicable 
Recruitment Status of Trial (India)  Open to Recruitment 
Publication Details   N/A 
Individual Participant Data (IPD) Sharing Statement

Will individual participant data (IPD) be shared publicly (including data dictionaries)?  

Response - NO
Brief Summary   Study Name: A Prospective, Observational, Multi-centre, Single-arm, Openlabel, Post-market Clinical Follow-up Study to Evaluate Safety and Performance of the Arthroscopy Implants for Shoulder in a Real-World Setting. 

Short Title: Arthroscopy ImplantsFor Shoulder 

Protocol ID, Version and Date: MHCPL/Arthroscopy Implants for Shoulder_Version 1.0.0_12- Sep-2024 

Study Device: Arthroscopy Implants for Shoulder

Indication: 1.Arthroscopy implants for the shoulder: These are indicated in all connective tissue tendon repairs together with the indications for shoulder-bankart lesion, rotator cuff rupture, slap lesion, acromioclavicular separation, biceps tenodesis, deltoid tear/separation, capsular shift, capsulolabral reconstruction, biceps tendon separation, ulnar and radial collateral ligament rupture/separation, scapholunate ligament tear/separation, and ulnar or radial collateral ligament. 2. Suture: Indicated in general soft tissue approximation, and/or ligation, including orthopedic procedures.

Objective: The study aims to evaluate the safety and performance of arthroscopy implants for the shoulder in subjects who require arthroscopy implantation in a real-world setting. 

Study Design: A Prospective, Observational, Multi-centre, Single-arm, Open label, Post-market Clinical Follow-up Study. 

Rationale of the Study Arthroscopy implants have become essential tools in minimally invasive orthopedic procedures, particularly for treating conditions in the shoulder, elbow, and hand/wrist joints. These procedures allow for targeted interventions, offering Subjects faster recovery times, less postoperative pain, and improved mobility compared to traditional open surgeries. However, there remains a need to comprehensively assess the safety and performance of these implants in realworld settings, where subject populations may vary significantly from clinical trials.This study is designed to evaluate the safety profile and performance of arthroscopy implants in diverse subject populations undergoing shoulder, elbow, and hand/wrist surgeries.







 
Close